Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
Rachel Jones(Addenbrooke's Hospital), David Jayne(University of Cambridge)
Cited by 226
Related Papers
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
|Annals of the Rheumatic Diseases|2023|635